أعضاء هيئة التدريس

Dr. Said Dermime obtained his PhD degree in immunology from Salford University, Manchester, UK in 1992. In 2015, Dr. Said joined NCCCR at HMC, Doha, Qatar as a director of the Translational Cancer Research Facility. Dr. Said Dermime is an adjunct associate professor at Hamad Bin Khalifa. He is also a mentor supervisor of PhD/master’s programs; he supervised 3 PhD and 2 master’s students.

Dr. Said published over 88 peer-reviewed articles in high impact factor journals. He also published several Book Chapters in prestigious publishers and is an editor/reviewer for many prestigious international scientific journals. Dr Said’s most prominent work includes identifying the cause of resistance to the drug retinoic acid in acute leukemia, discovering a novel leukemia vaccine against proteinase-3 as a target antigen and demonstrating that the lymphoma idiotype is a potential cancer vaccine target. He has also demonstrated, for the first time, the expression of the PD-L1 inhibitory molecule in breast cancer patients, showed direct evidence of PD-L1 induction in breast cancer cells and the involvement of both PD-L1 and regulatory T cells in the immune escape of breast cancer.

In addition, he was able to discover an antigen-specific regulatory T cell population in leukemia patients. Recently, he was able to demonstrate that the presence of anti-NY-ESO-1 integrated immunity and a specific cytokines/chemokines profile may potentially identify a response to PD-1 blockade in head and neck squamous cell carcinoma (HNSCC) patients. He was also able to show that a patient with metastatic gastric cancer benefiting from combined radio-immunotherapy treatment possesses persistent anti-NY-ESO-1 specific T cells and expresses differential biomarkers.